| Bioactivity | LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α[1]. |
| Invitro | The anti-TNF antibodies blocking the action of TNF alpha revolutionized therapy of TNF-related diseases such as Inflammatory Bowel Disease, lupus, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis. By neutralizing TNF activity, anti-TNF antibodies promote mucosal healing and induce long-term remissions in vivo. The main anti-TNF antibodies that are currently authorized encompass Infliximab, Etanercept, Adalimumab, Certolizumab and Golimumab[1]. |
| Name | LEESGGGLVQPGGSMK TFA |
| Shortening | LEESGGGLVQPGGSMK |
| Formula | C66H109F3N18O26S |
| Molar Mass | 1659.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
LEESGGGLVQPGGSMK TFA
CAS: F: C66H109F3N18O26S W: 1659.73
LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantita
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.